Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and card
Solid Biosciences Joins the Russell 3000 Index
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, to
This Planet Fitness Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Solid Biosciences Price Target Maintained With a $12.00/Share by Leerink Partners
Solid Biosciences Price Target Maintained With a $12.00/Share by Leerink Partners
Leerink Partners Upgrades Solid Biosciences(SLDB.US) to Buy Rating, Maintains Target Price $12
Leerink Partners analyst Joseph Schwartz upgrades $Solid Biosciences(SLDB.US)$ to a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 41.0
Express News | Solid Biosciences Inc : Leerink Partners Raises to Outperform From Market Perform
Solid Biosciences Price Target Maintained With a $20.00/Share by Piper Sandler
Solid Biosciences Price Target Maintained With a $20.00/Share by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on Solid Biosciences, Maintains $20 Price Target
Solid Biosciences Rises 15% off Expanded Sarepta Duchenne Indication
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients a
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersDermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million. Sarepta Therapeutics (NASDAQ:SRPT) shares r
Top Premarket Gainers
Sarepta Therapeutics (SRPT) shares surged almost 37% Friday premarket after the company secured an expanded US Food and Drug Administration approval for the company's gene therapy for Duchenne muscula
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival -- Barrons.com
By Josh Nathan-Kazis A second failure of a late-stage trial testing a gene therapy to treat Duchenne muscular dystrophy is bad news for patients, but Wall Street analysts say it could be good new for
Pfizer's Gene-therapy Trial Failure Boosts Sarepta's Stock
By Eleanor Laise Sarepta's gene therapy for Duchenne muscular dystrophy could soon get expanded label from FDA Shares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a pote
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20
Piper Sandler analyst Biren Amin maintains $Solid Biosciences(SLDB.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 41.4% and
Solid Biosciences(SLDB.US) Director Buys US$8,441.62 in Common Stock
$Solid Biosciences(SLDB.US)$ Director Kahn Clare purchased 1,100 shares of common stock on Jun 7, 2024 at an average price of $7.6742 for a total value of $8,441.62.Source: Announcement What is statem
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and card
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
Solid Biosciences Is Maintained at Neutral by JP Morgan
Solid Biosciences Is Maintained at Neutral by JP Morgan
Express News | JP Morgan Maintains Neutral on Solid Biosciences, Lowers Price Target to $10